Man Group’s China Biologic Products Holdings CBPO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q2
– Sell
-30,897
Closed -$3.66M – 2196
2021
Q1
$3.66M Buy
+30,897
New +$3.65M 0.02% 843
2020
Q3
– Sell
-21,912
Closed -$2.24M – 1946
2020
Q2
$2.24M Buy
21,912
+7,678
+54% +$822K 0.01% 1020
2020
Q1
$1.54M Sell
14,234
-141,327
-91% -$16.2M 0.01% 986
2019
Q4
$18.1M Buy
155,561
+90,469
+139% +$10.5M 0.06% 395
2019
Q3
$7.45M Buy
+65,092
New +$6.47M 0.03% 692
2019
Q1
– Sell
-60,540
Closed -$4.6M – 2173
2018
Q4
$4.6M Buy
60,540
+6,420
+12% +$472K 0.02% 813
2018
Q3
$4.33M Sell
54,120
-25,917
-32% -$2.41M 0.02% 1076
2018
Q2
$7.95M Buy
+80,037
New +$6.92M 0.03% 706

Man Group's CBPO Position: Q2 2021 in Review

Man Group sold out of China Biologic Products Holdings (CBPO) in Q2 2021, closing a stake of 30,897 shares — an estimated $3.66M sold.

Man Group first reported a position in CBPO in Q2 2018 and held it in 8 quarters. The position peaked at $18.1M in Q4 2019. 0 funds tracked by Wall St. Rank hold CBPO as of Q2 2021.

  • Man Group reported no remaining China Biologic Products Holdings position as of Q2 2021 after selling out during the quarter.
  • Man Group sold 30,897 China Biologic Products Holdings shares in Q2 2021, an estimated $3.66M.
  • Man Group first reported a position in China Biologic Products Holdings in Q2 2018 and held it in 8 quarters.
  • Man Group's China Biologic Products Holdings position peaked at $18.1M in Q4 2019.
  • 0 funds tracked by Wall St. Rank held China Biologic Products Holdings as of Q2 2021.

Based on Man Group's 13F filing for Q2 2021, filed 16 Aug 2021.